Semaglutide is effective in type 2 diabetes and obesity with schizophrenia

被引：0
|
作者：
Kaoru Noda
Takehiro Kato
Nao Nomura
Mayu Sakai
Sodai Kubota
Tokuyuki Hirose
Yanyan Liu
Yoshihiro Takahashi
Ken Takao
Masami Mizuno
Takuo Hirota
Tetsuya Suwa
Yukio Horikawa
Daisuke Yabe
机构：
[1] Gifu University Graduate School of Medicine,Department of Diabetes, Endocrinology and Metabolism
[2] Gifu University Graduate School of Medicine,Department of Rheumatology and Clinical Immunology
[3] Kansai Electric Power Medical Research Institute,Yutaka Seino Distinguished Center for Diabetes Research
[4] Tokai National Higher Education and Research System,Center for Healthcare Information Technology
[5] Kobe University Graduate School of Medicine,Division of Molecular and Metabolic Medicine
来源：
Diabetology International | 2022年 / 13卷
关键词：
GLP-1 receptor agonist; Schizophrenia; Obesity; Type 2 diabetes; Bodyweight;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：693 / 697
页数：4
相关论文
共 50 条
  • [21] Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
    Rune V. Overgaard
    Philip H. Delff
    Kristin C. C. Petri
    Thomas W. Anderson
    Anne Flint
    Steen H. Ingwersen
    Diabetes Therapy, 2019, 10 : 649 - 662
  • [22] Oral Semaglutide (Rybelsus) for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1583): : 166 - 168
  • [23] Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
    Iacobellis, Gianluca
    Fricke, Alexandra C. Villasante
    JOURNAL OF THE ENDOCRINE SOCIETY, 2020, 4 (04)
  • [24] Semaglutide injection for the treatment of adults with type 2 diabetes
    Chudleigh, Richard A.
    Bain, Stephen C.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (07) : 675 - 683
  • [25] Semaglutide for Chronic Kidney Disease in Type 2 Diabetes
    Passos, Rogerio da Hora
    Narciso, Roberto Camargo
    da Silva, Arnaldo Alves
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (18): : 1757 - 1757
  • [26] Cardiovascular Risk of Semaglutide in Patients With Type 2 Diabetes
    Marso
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (02) : 159 - 159
  • [27] Improvement of Insulin Sensitivity with Semaglutide in Type 2 Diabetes
    Kahl, S.
    DIABETOLOGE, 2019, 15 (04): : 347 - 348
  • [28] EndoBarrier®: a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes?
    Patel, Nisha
    Mohanaruban, Aruchuna
    Ashrafian, Hutan
    Le Roux, Carel
    Byrne, James
    Mason, John
    Hopkins, James
    Kelly, Jamie
    Teare, Julian
    OBESITY SURGERY, 2018, 28 (07) : 1980 - 1989
  • [29] EndoBarrier®: a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes?
    Nisha Patel
    Aruchuna Mohanaruban
    Hutan Ashrafian
    Carel Le Roux
    James Byrne
    John Mason
    James Hopkins
    Jamie Kelly
    Julian Teare
    Obesity Surgery, 2018, 28 : 1980 - 1989
  • [30] ENDOBARRIER® : A SAFE AND EFFECTIVE NOVEL TREATMENT FOR OBESITY AND TYPE 2 DIABETES?
    Mohanaruban, A.
    Patel, N.
    Ashrafian, H.
    Stoenchev, K.
    Le Roux, C.
    Penney, N.
    Kelly, J.
    Byrne, J.
    Hopkins, J.
    Mason, J.
    Teare, J.
    GUT, 2017, 66 : A205 - A205
12345